Nanobiotix SA (NBTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 14.39 is considered Undervalued compared with the five-year average of -4.52. The fair price of Nanobiotix SA (NBTX) is between 320.33 to 342.28 according to relative valuation method. Compared to the current price of 35.93 USD , Nanobiotix SA By Undervalued By 88.78%.

Relative Value

Fair Zone

320.33-342.28

Current Price：35.93

88.78%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Nanobiotix SA (NBTX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Nanobiotix SA (NBTX) has a current Price-to-Book (P/B) ratio of -13.21. Compared to its 3-year average P/B ratio of -33.62, the current P/B ratio is approximately -60.71% higher. Relative to its 5-year average P/B ratio of -8.79, the current P/B ratio is about 50.28% higher. Nanobiotix SA (NBTX) has a Forward Free Cash Flow (FCF) yield of approximately -3.45%. Compared to its 3-year average FCF yield of -8.54%, the current FCF yield is approximately -59.56% lower. Relative to its 5-year average FCF yield of -11.72%, the current FCF yield is about -70.53% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for NBTX competitors is 533.49, providing a benchmark for relative valuation. Nanobiotix SA Corp (NBTX.O) exhibits a P/S ratio of 14.39, which is -97.3% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of NBTX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of NBTX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is NBTX currently overvalued or undervalued?

What is Nanobiotix SA (NBTX) fair value?

NBTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Nanobiotix SA (NBTX) is between 320.33 to 342.28 according to relative valuation method.

How does NBTX's valuation metrics compare to the industry average?

The average P/S ratio for NBTX's competitors is 533.49, providing a benchmark for relative valuation. Nanobiotix SA Corp (NBTX) exhibits a P/S ratio of 14.39, which is -97.30% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Nanobiotix SA (NBTX) as of Mar 05 2026?

As of Mar 05 2026, Nanobiotix SA (NBTX) has a P/B ratio of -13.21. This indicates that the market values NBTX at -13.21 times its book value.

What is the current FCF Yield for Nanobiotix SA (NBTX) as of Mar 05 2026?

As of Mar 05 2026, Nanobiotix SA (NBTX) has a FCF Yield of -3.45%. This means that for every dollar of Nanobiotix SA's market capitalization, the company generates -3.45 cents in free cash flow.

What is the current Forward P/E ratio for Nanobiotix SA (NBTX) as of Mar 05 2026?

As of Mar 05 2026, Nanobiotix SA (NBTX) has a Forward P/E ratio of 163.39. This means the market is willing to pay $163.39 for every dollar of Nanobiotix SA's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Nanobiotix SA (NBTX) as of Mar 05 2026?

As of Mar 05 2026, Nanobiotix SA (NBTX) has a Forward P/S ratio of 14.39. This means the market is valuing NBTX at $14.39 for every dollar of expected revenue over the next 12 months.

NBTX Valuation